apid and adequate platelet inhibition is mandatory in all ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). New P2Y12 inhibitors, such as prasugrel and ticagrelor, have been proved beneficial in STEMI patients, with superior anti-ischemic action and a bleeding risk similar to clopidogrel. 1-3 Variable platelet inhibition is well-recognized following clopidogrel loading (LD), while in the clinical setting of STEMI, factors such as increased platelet reactivity and delayed clopidogrel absorption may further hamper efficiency and rapid platelet inhibition. 4-9 Nevertheless, clopidogrel remains a valuable antiplatelet drug, particularly in the case of non-availability of or contraindications to the newer agents.
Studies of platelet inhibition in the early hours of STEMI and following 600 mg clopidogrel LD are scarce. A minor decrease in platelet aggregation has been described at 4 h after 600 mg clopidogrel LD in a few STEMI patients, 9 while inadequate platelet inhibition has been reported at 18-48 h following PPCI. 10-12 Myocardial infarction, C-reactive protein and fibrinogen have been described as predictors of enhanced platelet reactivity 48 h after stenting. 12 In addition, older age, presence of diabetes, and a higher body mass index have been associated with reduced effectiveness of clopidogrel in non-ST-elevation acute coronary syndrome. 13 Because fresh thrombi have the highest proportion of platelets, the first few hours of STEMI are crucial for platelet inhibition, and the identification of factors associated with a weakened clopidogrel action might be particularly important. 14 In the present study in patients with STEMI undergoing PPCI, the aim was to evaluate predictive factors of high ontreatment platelet reactivity (HTPR) as early as 2 h following 600 mg of clopidogrel LD assessed on point-of-care P2Y12 function assay.
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Methods
The subjects consisted of eligible consecutive patients with STEMI undergoing PPCI who had been given 600 mg clopidogrel LD before intervention, and were screened with platelet function testing 2 h after LD. Screening took place in the context of the PRO-GR-4 study (Clinicaltrials.gov identifier NCT01338909). Briefly, this was a prospective, single-center, single-blind, investigator-initiated, randomized study of parallel design, in which eligible patients with STEMI undergoing PPCI and exhibiting HTPR 2 h after 600 mg clopidogrel LD, were randomized to either prasugrel reloading or double clopidogrel.
Patients were excluded if they had a history of bleeding diathesis, chronic oral anticoagulation or chronic thienopyridine treatment, contraindications to antiplatelet therapy, other antiplatelets LD, PCI or coronary artery bypass grafting <3 months before enrollment in the study, hemodynamic instability, platelet count <100,000/μl, hematocrit <30%, hemodialysis, anatomy not suitable for PCI, inability to swallow clopidogrel or vomiting after intake, and upstream or peri-PCI treatment with IIb/IIIa inhibitors. Patients with a history of stroke/transient ischemic attack and those weighing <60 kg or who were ≥75 years old were also excluded. All patients received 325 mg of acetylsalicylic acid and i.v. bolus unfractionated heparin (70 IU/kg) at first medical contact and underwent standard coronary angiography and PPCI with stent implantation. The type of stent implanted and the use of an additional 30 IU/kg of heparin or bivalirudin at the time of PPCI were left at the discretion of the operator.
Platelet reactivity was assessed as previously described. 15 Briefly, peripheral venous blood sample was drawn with a loose tourniquet through a short venous catheter inserted into a forearm vein exactly 2 h after clopidogrel ingestion. The first 2-4 ml of blood was discarded to avoid spontaneous platelet activation and blood was collected in 3.2% citrate (1.8-ml draw plastic Vacuette tubes; Greiner, Monroe, NC, USA). Platelet-function testing was performed using the VerifyNow (Accumetrics, San Diego, CA, USA) point-of-care P2Y12 function assay. Results are reported as P2Y12 reaction units (PRU), while a cut-off of 
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CrCl <60 ml/min (Cockcroft-Gault formula) 7 (7.6) 0 (0) 7 (11.1)
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Duration from pain onset to clopidogrel loading (h) 2. 
1.0
Data given as mean ± SD, median (range) or n (%). † Comparisons between patients with and without HTPR. HTPR, high on-treatment platelet reactivity; MI, myocardial infarction; PCI, percutaneous coronary intervention; FHCAD, family history of coronary artery disease; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitors; ATII, angiotensin II; CCB, calcium channel blockers; CrCl, creatinine clearance. Predictors of Platelet Reactivity in STEMI ≥235 PRU was considered an indication of HTPR. 16 Clinical and demographic characteristics were recorded and presented according to HTPR status at 2 h after clopidogrel LD. Clopidogrel use during transfer and before arrival to the catheterization laboratory was considered as upstream, and that given after the patient had arrived at the catheterization laboratory was classified as peri-interventional.
All patients gave informed consent for participation in the study, which was approved by the Ethics Committee of the University Hospital of Patras, Greece.
Statistical Analysis
Fisher's exact test and 2-sample t-test were used for comparison of categorical and normally distributed continuous data, respectively. Mann-Whitney U-test was used for comparison of skewed continuous data (presented as median [range]).
To assess potential risk factors for HTPR we used modified Poisson regression models for binary data (log-Poisson regression with robust estimate of variance), 17 because odds ratios produced by logistic regression may overestimate the magnitude of association between covariates and the outcome of interest when the outcome variable (HTPR status) is not rare. 18 We first assessed the unadjusted relative risks of HTPR for various patient characteristics and then a final multivariate model was fitted, including (simultaneously; the enter method) all the factors found to be related to HTPR status at the level of P≤0.2 on univariate analysis along with 3 other variables (diabetes mellitus, statin and omeprazole use) because of their potential effect on platelet reactivity.
All tests were 2-tailed and statistical significance was set at P<0.05. All statistical analysis was performed using SPSS for Windows version 16.0 (SPSS, Chicago, IL, USA).
Results
Out of 160 screened STEMI patients who had received 600 mg clopidogrel LD, 92 were eligible for platelet reactivity assessment at 2 h after 600 mg clopidogrel LD and were analyzed in this study. Patient demographic characteristics are listed in Table. Patients with HTPR had received upstream clopidogrel LD and pantoprazole more frequently, had lower admission hemoglobin and hematocrit, and tended to have impaired renal function compared to those with an adequate response to clopidogrel. On multivariate analysis (Figure) , upstream clopidogrel LD and creatinine clearance <60 ml/min were independently associated with higher risk for HTPR ( 
Discussion
The aim of the present study was to identify factors predicting early (ie, 2 h after clopidogrel LD) inadequate platelet inhibition in STEMI patients treated with PPCI. Upstream clopido- grel use and impaired renal function were found to be independent predictors of HTPR in the early phase of STEMI.
Adequate platelet inhibition is an integral therapeutic component in STEMI. Because fresh thrombi have the highest proportion of platelets, inhibiting platelet aggregation might be even more important in the very early course of STEMI. 14 We selected the 2-h time point for platelet reactivity assessment because an elapsed time of 2 h after 600 mg clopidogrel LD appears to be efficacious to achieve adequate platelet inhibition, at least in patients scheduled for cardiac catheterization as potential candidates for PCI. After 2 h, the level of platelet aggregation has been described not to change significantly with time after clopidogrel. 19 This may not be the case, however, in other clinical scenarios such as acute coronary syndrome, and particularly in STEMI. Indeed, only a minority of the present STEMI patients had successful platelet inhibition. Similarly to the present study, a minor decrease in platelet aggregation has been previously described at 4 h after 600 mg clopidogrel LD in a few STEMI patients. 9 The exact clinical significance of a so-frequent, early HTPR it is not clear. A high platelet reactivity in STEMI patients has been described to negatively impact on the clopidogrel effect, while predicting PPCI success on angiography, degree of ST-segment resolution, extent of myocardial necrosis, and short-and mid-term clinical outcome. 7,8, 10 In patients with STEMI undergoing unexpectedly delayed catheterization, a lower degree of platelet inhibition after clopidogrel LD was associated with larger intracoronary thrombus and worse post-PCI myocardial flow and perfusion. 20 The clinical sequelae of upstream or peri-interventional clopidogrel use are controversial. Data from registries and a metaanalysis showed that pretreatment with clopidogrel was associated with higher initial patency and improved outcome, including the combined endpoint of death and myocardial infarction at 1 year. [21] [22] [23] [24] In contrast, in the CRUSADE initiative involving 3,785 patients with STEMI undergoing PPCI, the risk of adverse outcomes and bleeding events were similar in the pre-vs. peri-PCI clopidogrel cohorts, with reinfarction occurring more frequently in the pre-PCI group. 25 Of note, in the only so far randomized study, the early use of 600 mg clopidogrel had a similar effect to that of placebo on flow rates, possibly because of the short clopidogrel to angiography time. 26, 27 Recently, Schäfer et al reported in a pharmacodynamic study that patients receiving 600 mg clopidogrel LD at first medical contact had weaker platelet inhibition at 24 h than those loaded peri-interventionally. 11 In the same line of evidence, we have described upstream clopidogrel use as an independent risk factor of HTPR at 2 h after LD. Conditions such as nausea, vomiting, stress, and pharmacological interventions such as morphine-based analgesia, might have all been involved in this paradox of early clopidogrel failure. 11 In the present study, impaired renal function independently predicted HTPR at 2 h after clopidogrel LD. Chronic kidney disease has been associated with a low platelet inhibitory response to clopidogrel in both diabetic and non-diabetic patients, while HTPR is extremely common in patients on hemodialysis. [28] [29] [30] In addition, the presence of low platelet response to clopidogrel has been linked to worse outcome after PCI. 31 No significant effect of chronic kidney disease on clopidogrel response, either acutely (following 600 mg) or after 1 month with 150 mg clopidogrel was found in patients with chronic kidney disease and non-STEMI undergoing PCI. Despite this, the authors advocated the use of higher than usual clopidogrel or alternative agents such as prasugrel or ticagrelor in highrisk chronic kidney disease patients. 32 Indeed, in the Study of Platelet Inhibition and Patient Outcomes (PLATO) trial, most of the superiority provided by ticagrelor vs. clopidogrel was confined to patients with impaired renal function. 33 Several other factors have been reported to predict HTPR in other conditions such as stable coronary artery disease, cardiovascular disease or non-STEMI heart conditions. These include age, body mass index, fibrinogen, diabetes mellitus, female gender, non-Caucasian ethnicity, use of proton-pump inhibitors, smoking, and CYP2C19*2 carrier status. 13,34- 36 The present pharmacodynamic results are in contrast to the aforementioned clinical studies suggestive of the beneficial action of early, 'as soon as possible', upstream clopidogrel treatment in patients with STEMI undergoing PPCI. But the identification of factors associated with HTPR, that is, upstream clopidogrel and/or impaired renal function, although not supported by clinical studies, might be a reason for the use of more potent P2Y12 inhibitors such as prasugrel or ticagrelor, or even adjunctive use of IIb/IIIa inhibitors.
There were several limitations to the present study. Only 1 method for platelet function testing was used and the results apply only for this method. But the assay used has been found to correlate well with light transmittance aggregometry, which is considered to be the gold standard. Pharmacokinetic samples were not collected simultaneously with the samples for platelet function analysis to allow assessment of relationships between the 2 and the role of drug absorption. The threshold for HTPR in the present study was obtained from receiver operating characteristic analysis in post-PCI studies. It is not clear whether the same threshold has a similar predictive value in PPCI/STEMI patients. Platelet reactivity prior to the event was not known and a higher baseline value in patients receiving upstream treatment cannot be excluded. Because hemodynamic instability and/or intubation have been associated with impaired platelet inhibition after clopidogrel LD, is important to note that the present results apply to patients who are hemodynamically stable. 37 The present sample size did not provide sufficient power to allow detection of other important relationships between HTPR status and variables of interest, such as the presence of diabetes mellitus.
In conclusion, the present findings suggest that in patients with STEMI undergoing PPCI, upstream clopidogrel and impaired renal function independently predict HTPR, assessed as early as 2 h following 600 mg clopidogrel LD on point-ofcare P2Y12 function assay. Further studies for possible antiplatelet treatment tailoring in such patients are needed.
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